Monitoring Cancer Treatment – September 2021

Top Curve image

Monitoring Cancer Treatment – September 2021

How do we measure success or failure in the treatment of cancer?

One question that I get asked more frequently than any other is “how do you measure progress or success in treatment?”.

The answer is multi-faceted.

The first step is the monitoring of conventional cancer markers that can be ordered in a regular blood test. 

  • These are proteins that can be detected in the blood that are secreted by certain kinds of cancer cells. The limiting factor with these tests is they are only secreted by a small number of cancers and do not detect or monitor most types of tumor cells.
  • We also frequently perform standard blood tests (complete blood counts, chemistry panels and a number of other tests) that allow us to watch the condition of the liver, kidneys, protein levels, hemoglobin and electrolytes as well as specific cell counts to make sure they stay within normal limits.

The next way we have for monitoring success in treatment is the various types of scans available in conventional medicine. 

  • They would be CT & PET scans, MRI’s, and ultrasounds. The problem with this method of monitoring is the limitation of exposure to radiation by some of them (CT & PET). So they cannot be done very frequently.
  • The potential limitation with the MRI’s and Ultrasounds is that they tell everything about the size of the tumor but tell us nothing about the level of cancer activity within the tumor or the number of circulating cancer cells in the blood stream.

Another often used test is the Nagalase blood test

  • Nagalase is an enzyme that is secreted by all cancer cells for the purpose of hiding themselves from the immune system. It does its job by masking the presence of the tumor cells from the major cancer killing cells in the immune system…the macrophage cell. 

The good thing about nagalase is that we can monitor the level by a simple, inexpensive blood test. 

(We must make note, however, that Nagalase is not a “stand alone” diagnostic tool. It can be swayed by viral loads or excessive exercise.)

  • The shortcoming of this test is that it cannot tell us where the cancer is located. It can also be elevated into an abnormal range by a viral infection or by frequent severe anaerobic exercise workouts. What this means is that it takes some interpretation to get an accurate idea of what is happening with the cancer. It is not black and white.

To learn more about how we neutralize nagalase with GcMAF click here.

Many times monitoring requires seeing the pattern of blood tests over time (once a month) rather than relying on any individual specific reading.

Numbers of circulating tumor cells can also be measured by a specific blood test. Of course, over time during treatment we would want to see decreasing numbers.

We also have the in-office evaluations during the visits with Dr. Eslinger that consist of the live blood display and Zyto scans.

It is the combination of all these tests and the interpretation of them that gives us an understanding of whether or not we need to make changes in the protocol until we start seeing progress.

All of this may seem complicated and that is because it is. It takes years of training and experience to do it properly. No changes in the protocol are done frivolously and a lot of the decision making happens behind the scenes. 

The end result, hopefully, is providing the most effective therapy program for each individual patient.

Dr. Eslinger will review your records and discuss treatment options. The information gathered will help in the decision making process. Our patient liaison will be in contact after the Medical Records Evaluation to go over costs and scheduling.


Become a Patient
Visit our website
Reno Integrative Medical Center
6110 Plumas St. Ste. B, Reno, Nevada 89519
Phone: 775-829-1009 1-800-994-1009

Call Now ButtonCall Now